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Abstract Platinum-based antitumor agents have been the
mainstay in cancer chemotherapy for many human malig-
nancies. Drug resistance is an important obstacle to
achieving the maximal therapeutic efficacy of these drugs.
Understanding how platinum drugs enter cells is of great
importance in improving therapeutic efficacy. It has been
demonstrated that human high-affinity copper transporter 1
(hCtr1) is involved in transporting cisplatin into cells to
elicit cytotoxic effects, although other mechanisms may
exist. In this communication, we demonstrate that cisplatin
transcriptionally induces the expression of hCtr1 in time-
and concentration-dependent manners. Cisplatin functions
as a competitor for hCtr1-mediated copper transport,
resulting in reduced cellular copper levels and leading to
upregulated expression of Sp1, which is a positive regu-
lator for hCtr1 expression. Thus, regulation of hCtr1
expression by cisplatin is an integral part of the copper
homeostasis regulation system. We also demonstrate that
Ag(I) and Zn(II), which are known to suppress hCtr1-
mediated copper transport, can also induce hCtr1/Sp1
expression. In contrast, Cd(II), another inhibitor of copper
transport, downregulates hCtr1 expression by suppressing
Sp1 expression. Collectively, our results demonstrate
diverse mechanisms of regulating copper metabolism by
these heavy metals.
Keywords Cisplatin  High-affinity copper
transporter  Sp1  Copper homeostasis  Platinum
drug resistance
Abbreviations
CCO Cytochrome c oxidase
CdAc2 Cadmium acetate
Ctr1 High-affinity copper transporter 1
hCtr1 Human high-affinity copper transporter 1
mRNA Messenger RNA
RPA RNase protection assay
SCLC Small cell lung cancer
SD Standard deviation
siRNA Small interfering RNA
SOD1 Superoxide dismutase 1
ZnAc2 Zinc acetate
Introduction
Platinum-based drugs have been the mainstay of cancer
chemotherapy for a broad spectrum of human malignancies
for the last three decades [1, 2]. However, resistance to
these drugs has been an obstacle to their effective use [3–
5]. Although many mechanisms have been described for
platinum drug resistance, a well-recognized and important
mechanism of resistance is the reduced transport or
enhanced efflux (or both) of cellular platinum drugs [6, 7].
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Multiple mechanisms are involved in platinum drug
transport. Cisplatin—cis-[PtCl2(NH3)2]—may enter cells
by means of passive diffusion or endocytosis [3, 8, 9] and
by high-affinity copper transporter 1 (Ctr1). The involve-
ment of Ctr1 in cisplatin transport was initially demon-
strated using yeast genetics which showed that deletion of
CTR1 resulted in impaired cisplatin transport and cisplatin
resistance [10, 11]. In a Ctr1-knockout murine embryonic
fibroblast model, although Ctr1-/- cells accumulated only
5.7 % of the amount of copper that Ctr1?/? cells accu-
mulated during 1 h exposure to 2 lM copper, the amount
of cisplatin accumulated in these Ctr1-/- cells was
35–36 % of that accumulated in Ctr1?/? cells [8]. More-
over, cisplatin-resistant human cell lines exhibited reduced
cisplatin contents, and the resistance was restored when
CTR1 was introduced into these cells [12–14]. These
results demonstrated that Ctr1 plays an important role in
cisplatin resistance.
In clinical studies, the human Ctr1 (hCtr1) expression
level in tumor tissue specimens has been positively corre-
lated with the treatment outcome of patients who had
undergone platinum-based cancer chemotherapy [14–16].
Using cultured cell models, we recently demonstrated that
copper chelators could upregulate the hCtr1 level to a
greater extent in cisplatin-resistant cells than in cisplatin-
sensitive cells, leading to resensitization of the resistant
cells to cisplatin [14]. These findings provided a mecha-
nistic basis for the first study in humans using a copper
chelator to overcome platinum resistance in ovarian cancer
patients [17].
The observation that copper chelation enhances hCtr1
expression was part of our previous investigation into the
mechanisms of mammalian copper homeostasis regulation.
We demonstrated that copper chelation induces the
expression of transcription factor Sp1, which binds the
promoters of SP1 and CTR1, thereby upregulating their
expression, whereas copper overload shuts down expres-
sion of SP1 and CTR1 by dissociating Sp1 from their
promoters. Thus, mammalian copper homeostasis is
transcriptionally regulated within a loop consisting of Sp1,
hCtr1, and copper in a three-way mutually regulated
manner [6, 18]. Posttranslational regulation which involves
the internalization and subcellular processing of hCtr1 in
response to extracellular copper availability has also been
reported [6],
Although much has been learned on the regulation of
hCtr1 expression by copper bioavailability, whether hCtr1
is regulated by cisplatin and other metal ions is not known.
In this communication, we demonstrate that cisplatin,
Ag(I), Zn(II), and Cd (II) can also regulate hCtr1 expres-
sion through interference with copper homeostasis, thus
revealing a regulatory mechanism of copper homeostasis
by cisplatin and heavy metal ions.
Materials and methods
Cell lines and reagents
Human ovarian cancer cell lines (IGROV1, SKOV-3, 59M,
and OVCAR-3) were obtained from Gordon Mills (MD
Anderson Cancer Center). The small cell lung cancer
(SCLC) cell line was obtained from N. Savaraj (University
of Miami School of Medicine, Miami, FL, USA). Poly-
clonal anti-hCtr1 antibody obtained using the extracellular
50 amino acid residues of hCtr1 as the immunogen was
previously described [14]. Sp1 antibody was obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Cis-
platin was purchased from Sigma-Aldrich (St Louis, MO,
USA). Other chemicals were of chemical grade.
Cell culture and determination of hCtr1 and Sp1
messenger RNA and protein expression by the RNase
protection assay and Western blotting
Cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10 % fetal bovine serum at 37 C in a 5 %
CO2 atmosphere. Cells at the exponential growth stage were
treated with cisplatin, CuSO4, AgNO3, zinc acetate (ZnAc2) or
cadmium acetate (CdAc2). Procedures for RNA extraction
and determination of hCtr1 messenger RNA (mRNA) and Sp1
mRNA levels by the RNase protection assay (RPA) using the
isoform-specific probes were described previously [12, 13].
Procedures for Western blotting were described previously
[12, 13]. Owing to the constraint of the copper homeostasis
regulatory loop [6], the magnitudes of hCtr1 and Sp1 regu-
lation by cisplatin and heavy metals were low at the mRNA
and protein levels. Thus, the conditions for the RPA and
Western blotting needed to be optimized.
Images were taken only under exponential exposure
conditions. Images were scanned in grayscale at a resolu-
tion of 600 dpi. The band intensities were measured with
ImageJ [19] and normalized using the intensity of tubulin
for Western blots or 18S for RPA as references.
All statistical analyses were conducted from at least three
measurements using the two-tailed t test, and the results
were expressed as the mean ± the standard deviation (SD);
p \ 0.05 was considered as statistically significant.
Copper and cisplatin transport assays, determination
of drug sensitivity, and measurement of Km and Vmax
For copper transport analyses, 2 9 105 cells per well were
plated in six-well plates. After 12 h, fresh medium contain-
ing various concentrations of CuSO4 was added and cultured
for various time intervals. Cells were washed four times with
phosphate-buffered saline and then lysed in 400 ll of lysis
buffer [13]. Cellular copper content was measured using
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atomic absorption spectroscopy. For cisplatin transport
measurement, 5 9 106 cells per well were treated with
various concentrations of cisplatin. Cells were harvested and
lysed in 50 ll of benzethonium hydroxide at 50 C for 16 h
[13]. The lysates were acidified with 200 ll of 0.3 N HCl,
and the platinum content was determined by a Zeeman
atomic absorption spectrometer (AA240Z) equipped with a
GTA12 graphite atomizer according to the procedure
described previously [14]. The results were from at least
three measurements and are given as the mean ± the SD.
Drug sensitivity tests were performed according to the
procedure described previously [12]. In brief, cells were
grown in 96-well plates (104 cells per well) and were
treated with various concentrations of cisplatin, CuSO4, or
CdAc2, and cell sensitivity was measured by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assay. Experiments were performed with eight replicates at
each dose. Values represent the mean ± the SD.
Measurements of the Vmax and Km values were done
according to the procedures previously described [13]. Vmax
and Km were calculated according to the Michaelis–Menten
equation: 1/V = 1/Vmax ? Km/(Vmax 9 [S]), where [S] is
the copper or cisplatin concentration, and V is the copper or
platinum concentration inside the cells at a given time point
according to the procedures previously described [13].
Results
Upregulation of hCtr1 and Sp1 expression by cisplatin
Cisplatin has been the dominant chemotherapeutic drug for
treating ovarian cancers [2]. In this work, we used four
ovarian cancer cell lines, two from patients who had never
been treated with cisplatin (IGROV1 [20] and M59 [21])
and two from cisplatin-relapsed patients (SKOV-3 [22] and
OVCAR-3 [23]). We previously demonstrated that SKOV-3
and OVCAR-3 express reduced hCtr1 mRNA levels as
compared with those in IGROV1 and 59M [14]. To inves-
tigate whether hCtr1 expression is regulated by cisplatin in
these cell lines, we grouped these four cell lines into two
pairs, i.e., IGROV1 vs SKOV-3 and 59M vs OVCAR-3;
each pair consisted of one high hCtr1 expresser (IGROV1
and 59M) and one low hCtr1 expresser (SKOV-3 and
OVCAR-3). We treated these cells with various concen-
trations of cisplatin for 20 h, and RPA was used to deter-
mine hCtr1 mRNA levels in the treated cells. We found that
in all four cell lines, a cisplatin-concentration-dependent
increase of hCtr1 mRNA expression was observed, and that
the magnitudes of hCtr1 mRNA induction by cisplatin were
higher in cells expressing reduced levels of hCtr1 mRNA
than in cells expressing elevated levels of hCtr1 mRNA.
Densitometric analyses showed that OVCAR-3 cells, which
express the lowest level of hCtr1 of the cell lines tested, had
the highest level (2.5-fold) of hCtr1 mRNA induction,
whereas 59M cells, which have the highest level of hCtr1,
had the lowest level (1.4-fold) (Fig. 1, a, b, right). These
results demonstrated that cells with reduced hCtr1 expres-
sion levels have greater magnitudes of hCtr1 induction by
cisplatin than do those expressing reduced levels of hCtr1.
These results are consistent with those of our previous study
using copper-lowering agents [14].
We next investigated whether upregulation of hCtr1
mRNA by cisplatin could be seen at the protein level using
anti-hCtr1 antibody. This antibody was prepared in our
laboratory in 2010 and has been kept at -80 C [14]. To
Fig. 1 Regulation of human
high-affinity copper
transporter 1 (hCtr1) expression
in ovarian cancer cell lines by
cisplatin. Induction of hCtr1
messenger RNA (mRNA)
expression by different
concentrations of cisplatin as
indicated for 20 h in a the
IGROV1 and SKOV-3 cell lines
and b the 59M and OVCAR-3
cell lines. The hCtr1 mRNA
levels were determined by the
RNase protection assay (RPA),
and the percent changes are
correspondingly shown on the
right (n = 3). cDDP cisplatin
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determine whether this antibody was still reliable for probing
hCtr1 protein expression, we performed Western blotting
using whole cell extracts prepared from SCLC cells and
cisplatin-treated SCLC cells, and SCLC cells transfected
with a dominant-negative mutant CTR1 complementary
DNA (a positive control for hCtr1 expression). Consistent
20 J Biol Inorg Chem (2014) 19:17–27
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with our previous findings [14], this antibody reacts with two
proteins (approximately 55 and 23 kDa) (Fig. 2a), but only
the 23-kDa signal, which corresponds to the molecular mass
of an unmodified hCtr1 monomer, was increased in the cis-
platin-treated cells and the CTR1-transfected cells. This
antibody stains the cell membrane with minor cytoplasmic
staining, consistent with the primary cytologic location of
hCtr1 (Fig. 2c). These results demonstrated that the hCtr1
antibody was still reliabe for Western blotting.
We also determined the expression levels of Sp1 in these
cell extracts by using a commercial antibody. Anti-Sp1
antibody detected only a 98-kDa signal, consistent with the
molecular mass of Sp1. The signals were also increased in
cisplatin-treated SCLC cells (Fig. 2b), and in CTR1-trans-
fected SCLC cells owing to expression of the dominant-
negative hCtr1 recombinant, which acts much like a cop-
per-lowering agent [14, 18].
Protein and mRNA levels of hCtr1 and Sp1 in SCLC
cells treated with 10 lM cisplatin for various times were
determined by the RPA (Fig. 2d, top) and Western blotting
(Fig. 2d, bottom). Upregulation of hCtr1 and Sp1 mRNA
occurred between 0.5 and 2 h after the treatment and
plateaued 6–8 h later with approximately fourfold to sev-
enfold increases. Sp1 and hCtr1 mRNA and protein
induced by cisplatin followed the same kinetics, suggesting
that the induction is coordinated. These results demon-
strated that the regulation of hCtr1 and Sp1 expression by
cisplatin is mainly at the mRNA level.
We observed a concentration-dependent induction of
hCtr1 and Sp1 expression in IGROV1 cells (Fig. 2e) and
SKOV-3 cells (Fig. 2f) treated with cisplatin for 16 h.
Induction of hCtr1 and Sp1 expression could be seen at
2.5 lM, a concentration relevant to the therapeutic dose.
Induction of hCtr1 and Sp1 expression was generally cor-
related at the mRNA and protein expression levels. Thus,
from the investigation of five cell lines, we concluded that
hCtr1 and Sp1 are coordinately upregulated by cisplatin in
human cancer cells.
Induction of hCtr1 by cisplatin is regulated by Sp1
To investigate whether enhanced hCtr1 expression is reg-
ulated by co-induced Sp1, we treated IGROV1 and SKOV-
3 cells with Sp1 small interfering RNA (siRNA) followed
by 10 lM cisplatin for 16 h. Knockdown of Sp1 by siRNA
almost completely suppressed the expression of hCtr1
mRNA, but hCtr1 mRNA levels remained unchanged in
cells treated with scrambled siRNA (Fig. 3a, b, left, lane
Fig. 3 Knockdown of Sp1
suppresses cisplatin-induced
hCtr1 expression. IGROV1
(a) and SKOV-3 (b) cells were
treated with or without 10 lM
cisplatin for 16 h in the
presence of scrambled small
interfering RNA (siRNA)
(denoted by S) or Sp1 siRNA as
indicated. Levels of hCtr1
mRNA were determined by the
RPA using 18S ribosomal RNA
as a reference (left).
Densitometric measurements of
percent changes are shown on
the right. Asterisk p \ 0.05 by
Student’s t test (n = 3), cDDP
cisplatin
Fig. 2 Characterizations of anti-hCtr1 antibody and analysis of hCtr1
induction by cisplatin. a, b Western blot of cell extracts prepared from
different cell sources as indicated using anti-hCtr1 antibody (a) and
anti-Sp1 antibody (b). c Immunofluorescence images of hCtr1
detected by anti-hCtr1 antibody (top) and the same cells stained by
propidium iodide (PI) (middle), and the merged image (bottom).
d Time-dependent induction of hCtr1 and Sp1 expression by cisplatin.
Small cell lung cancer (SCLC) cells were treated with 10 lM cisplatin
for the times indicated. Expression levels of hCtr1 and Sp1 mRNA
and protein were determined by the RPA (top three rows) and
Western blotting (bottom three rows), respectively. e, f Concentra-
tion-dependent induction of IGROV1 or SKOV-3 cells treated with
various concentrations of cisplatin as indicated for 16 h. Expression
of hCtr1 and Sp1 mRNA and protein was similarly determined.
Densitometric analyses of the expression levels shown in d–f are
correspondingly shown below the Western blots (n = 3). cDDP
cisplatin
b
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2). Treating cells with cisplatin induced hCtr1 and Sp1
expression, and Sp1 siRNA suppressed the induction of
both in both cell lines. These results demonstrated that the
upregulation of hCtr1 by cisplatin is controlled by Sp1.
Suppression of cisplatin-induced hCtr1 and Sp1
expression by copper
We hypothesized that induction of hCtr1 and Sp1 by cis-
platin was due to competition for hCtr1-mediated copper
transport by cisplatin resulting in reduced cellular copper
levels. Under this scenario, cisplatin functions like a cop-
per-lowering agent for Sp1/hCtr1 induction. Although
reduced copper levels can be verified by reduced activities
of copper-dependent enzymes, such as superoxide dismu-
tase 1 (SOD1) and mitochondrial cytochrome c oxidase
(CCO) [24, 25], we considered that these biomarkers are
inadequate for determining cellular copper status in the
cisplatin-treated cells, because SOD1 and CCO are redox-
sensitive enzymes [26] and cisplatin is a potent redox-
generating agent [27]. Consistent with this notion, we found
that the antitumor drug elesclomol (STA4783), which is a
strong pro-oxidant copper chelator [28], induced hCtr1
expression but that SOD1 and CCO activities were also
increased (our unpublished data). Ceruloplasmin, another
frequently used copper biomarker [24, 25], would not be
suitable because cisplatin can also bind ceruloplasmin [29].
To demonstrate that cisplatin competes against copper in
hCtr1-mediated transport, we determined the uptake of
copper in the presence of cisplatin and vice versa. Treating
IGROV1 cells with increased concentrations of copper
resulted in increased cellular copper levels, but these were
Fig. 4 Reciprocal inhibition of copper and cisplatin uptake. a Left
inhibition of copper uptake by cisplatin in IGROV1 cells. Cells were
treated with different concentrations of CuSO4 as indicated alone or
with 10 lM cisplatin for 2 h. Intracellular copper contents were
determined by atomic absorption spectroscopy. a Right inhibition of
cisplatin uptake by CuSO4. IGROV1 cells were treated with different
concentrations of cisplatin as indicated alone or with 100 lM CuSO4
for 2 h. Intracellular platinum contents were determined by atomic
absorption spectroscopy. b Inhibition of cellular copper accumulation
by cisplatin in IGROV1 cells (left) and SKOV-3 cells (right) cells.
Cells were treated with different concentrations of cisplatin for 4 h.
Cellular copper and cisplatin were measured. c Kinetic parameters for
copper and cisplatin uptake alone or in combination in IGROV1 cells.
The values represent the mean ± the standard deviation (SD)
(n = 3). cDDP cisplatin
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suppressed by the addition of 10 lM cisplatin (Fig. 4a,
left). Likewise, treating IGROV1 cells with increased
concentrations of cisplatin increased its uptake, and addi-
tion of 100 lM CuSO4 suppressed its transport (Fig. 4a,
right).
To determine whether cisplatin treatment would reduce
the steady-state levels of cellular copper levels, we treated
IGROV1 and SKOV-3 cells with various concentrations
(5–80 lM) of cisplatin for 4 h. Figure 4b shows that reduced
cellular copper contents correspond to increased concentra-
tions of cisplatin in both cell lines. These results suggest that
cisplatin treatment resulted in reduced copper accumulation.
To more precisely determine how cisplatin affects
hCtr1-mediated Cu(I) transport and vice versa, we mea-
sured the kinetic constants Km and Vmax in IGROV1 cells.
Km for copper uptake was 5.31 ± 0.31 lM (Fig. 4c),
which is in agreement with the values reported for Ctr1-
mediated Cu(I) transporters in a variety of organisms
(between 1 and 6 lM) [13, 30, 31]. In the presence of
cisplatin, however, Km increased to 11.02 ± 1.08 lM
(about a twofold increase), whereas Vmax reduced from
17.93 ± 1.33 to 7.76 ± 0.84 pmol/mg protein/min (more
than twofold reduction), indicating that cisplatin interferes
with hCtr1-mediated Cu(I) transport. Km for cisplatin
uptake was 13.29 ± 1.14 lM, which is also in agreement
with the previous result (11–13 lM) [13]. In the presence
of CuSO4, Km for cisplatin uptake was 18.20 ± 1.14 lM (a
37 % increase), whereas Vmax decreased from
24.48 ± 1.31 to 21.58 ± 11.18 pmol/mg protein/min, only
11 % reduction. These results further suggest that cisplatin
and Cu(I) mutually interfere with each other in their
transport [32] and strongly support the notion that cisplatin
is a weak substrate of hCtr1.
To substantiate these results, we investigated whether
upregulation of hCtr1 and Sp1 could be suppressed by
CuSO4. IGROV1 and SKOV-3 cells were treated with
10 lM cisplatin in the presence of increased concentrations
of CuSO4 for 16 h. We found approximately 2.5-fold and
1.7-fold induction of hCtr1 and Sp1 mRNA, respectively,
in cells treated with cisplatin alone. SP1 and hCtr1 mRNA
Fig. 5 Effect of copper on
cisplatin-induced hCtr1 and Sp1
mRNA expression and
cytotoxicity in cultured cells.
a IGROV1 and SKOV-3 cells
were treated with 10 lM
cisplatin for 16 h in the
presence of various
concentration of CuSO4. Sp1
and hCtr1 mRNA levels were
determined by the RPA.
b Densitometric measurements
of the RPA results shown in
a (n = 3). c Cytotoxicity tests
of IGROV1 and SKOV-3 cells
treated with cisplatin alone or
cisplatin plus increased
concentrations of CuSO4, or
different concentrations of
CuSO4 without cisplatin for
16 h (D1 series) or for 3 days
(D3 series). Cytotoxicities were
determined by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide
assay (mean ± SD, eight
replicates in each dose). cDDP
cisplatin
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expression levels were reduced 50–70 % when 50 lM
CuSO4 was included, and were completely suppressed
when 100 or 200 lM CuSO4 was used (Fig. 5a, b, lanes 5
and 6). These results demonstrated that induction of hCtr1/
Sp1 expression by cisplatin is due to reduced cellular
copper content.
We next investigated whether inhibition of cisplatin-
induced hCtr1 expression by copper would reduce cis-
platin’s cell-killing capacity. We measured the survival
rates of IGROV1 and SKOV-3 cells treated with 10 lM
cisplatin plus increased concentrations of CuSO4 (like the
treatment shown in Fig. 5a), the same concentration range
of CuSO4 without cisplatin, or 10 lM cisplatin alone for
16 h. Treating IGROV1 and SKOV-3 cells with 10 lM
cisplatin alone resulted in survival rates of 92.9 ± 4.7 and
95.3 ± 4.8 %, respectively. The survival rates decreased in
a concentration-dependent manner in IGROV1 and SKOV-
3 cells treated with 10 lM cisplatin plus 200 lM CuSO4,
reaching 72.9 ± 4.1 and 75.9 ± 5.2 %, respectively,
whereas they were 81.8 ± 4.1 and 85.7 ± 5.2 %, respec-
tively, for treatment with 200 lM CuSO4 alone (Fig. 5c).
Treating IGROV1 and SKOV-3 cells with 200 lM
CuSO4 for 3 days resulted in survival rates of 25.9 ± 0.6
and 50.8 ± 0.16 %, respectively. In the presence of 10 lM
cisplatin, the survival rates correspondingly reduced to
5.1 ± 0.12 and 15.9 ± 0.12 %, respectively (Fig. 5c).
These results demonstrated that despite the suppression of
cisplatin-induced hCtr1 mRNA expression by copper as
shown in Fig. 5a, no corresponding reduction of cellular
toxicity was found.
Regulation of hCtr1 and Sp1 expression by metal ions
A previous study demonstrated that Ag(I), Zn(II), and
Cd(II) ions inhibited hCtr1-mediated Cu(I) uptake in
hCtr1-transfected or nontransfected HEK293 cells [33].
Fig. 6 Induction of hCtr1 and Sp1 mRNA expression by different
metal ions. IGROV1 and SKOV-3 cells were treated with zinc acetate
(ZnAc2) (a), AgNO3 (b), and cadmium acetate (CdAc2) (c) at the
concentrations indicated for 16 h. Expression of hCtr1 and Sp1
mRNA was determined by the RPA. Corresponding relative levels of
induction (as a percentage) are shown on the right. d Suppression of
copper uptake by CdAc2. IGROV1 cells (left) or SKOV-3 cells (right)
were treated with different concentrations of CdAc2 for 16 h. Cells
were harvested and cellular copper levels were determined (n = 3)
24 J Biol Inorg Chem (2014) 19:17–27
123
However, the underlying mechanisms were not investi-
gated. We determined the expression of hCtr1 and Sp1
mRNA in IGROV1 and SKOV-3 cells treated with dif-
ferent concentrations of ZnAc2, AgNO3, or CdAc2 for
16 h. We found concentration-dependent increased
expression of hCtr1 and Sp1 by ZnAc2 (Fig. 6a) and
AgNO3 (Fig. 6b), with maximal induction levels of
approximately twofold for hCtr1 mRNA but 1.2-fold to
1.5-fold for Sp1 mRNA. In contrast, even 1 lM CdAc2
suppressed the expression of hCtr1 and Sp1 mRNA
(Fig. 6c). Suppression of hCtr1 expression by CdAc2 cor-
responded to reduction of copper levels (Fig. 6d). These
results suggest that Ag(I) and Zn(II), like cisplatin, func-
tion as competitors for hCtr1-mediated Cu(I) transport. In
contrast, inhibition of copper uptake by Cd(II) was asso-
ciated with downregulation of hCtr1 resulting from inhi-
bition of Sp1 expression. We and others previously
demonstrated that Cd(II) transport is mainly mediated by
ZIP8 (SLC39A8) [34, 35]. Here, we demonstrated that
inhibition of copper uptake by Cd(II) is due to suppression
of hCtr1 expression through the downregulation of Sp1.
These results revealed diverse mechanisms of inhibition of
hCtr1-mediated copper transport by these heavy metal ions.
Discussion
The major finding of this study is that cisplatin induces
hCtr1 expression through the co-induced expression of
Sp1, which functions as a positive regulator for hCtr1
expression. This finding reveals a new role of hCtr1 in the
cisplatin pharmacology and provides important insights
into how cisplatin may use hCtr1 in eliciting its antitumor
activity in cancer chemotherapy.
Induction of hCtr1 by cisplatin treatment could be seen
at the mRNA and protein levels. Although the magnitudes
of induction were small, the results were highly repro-
ducible. Changes of hCtr1 expression were demonstrated in
concentration- and time-dependent manners. The small
magnitudes of the changes reflect the tightly controlled
copper homoeostasis regulation mechanism [6]. Our ability
to detect small changes relied on the use of appropriate
assay tools: an isoform-specific RPA probe for mRNA and
a well-characterized anti-hCtr1 antibody in Western blot-
ting. Polyclonal anti-hCtr1 antibodies reported by different
laboratories detected different molecular masses of hCtr1
monomer, i.e., 28 kDa [36], 24 kDa [37], 35 kDa [38], and
24 and 36 kDa [39]. The 23–24-kDa protein corresponds to
the unmodified hCtr1 monomer, which consists of 190
amino acid residues. The 35–36-kDa protein is considered
to be glycosylated hCtr1 [24, 38]. Although the roles of
glycosylated hCtr1 and native hCtr1 in copper transport
remain to be critically investigated, we demonstrated in
this and previous communications [14] that the expression
levels of 23-kDa hCtr1 are well correlated with hCtr1
mRNA levels within the context of overall copper
homeostasis regulation. However, the antibody that rec-
ognizes 35-kDa hCtr1 failed to detect hCtr1 changes in
human embryonic kidney cells that overexpressed hCtr1 by
transfection [40]. Because our antibody recognizes
unmodified hCtr1 monomer, the signal shown in the
Western blot is discrete, whereas the 35-kDa signal is
general is more diffuse because of different degrees of
protein modification. The discrete signal can be readily
quantified as demonstrated in this study.
The demonstration that cisplatin regulates hCtr1
expression as an integral part of mammalian copper
homeostasis regulation lends further support for the
importance of hCtr1 in cisplatin transport. The controversy
surrounding cisplatin as a substrate for hCtr1 relates to its
molecular size and charge [40]. Although the molecular
size of cisplatin is greater than the ‘‘narrowest opening’’ of
trimeric hCtr1, recent studies suggest that prior to entering
a cell, cisplatin is activated by interacting with the extra-
cellular methionine clusters of hCtr1, resulting in release of
the carrier ligand [41–43] and formation of the
[Pt(Met)Cl(NH3)2]
? intermediate. The radius of this plat-
inum intermediate (2.4 A˚) [44] is smaller than the radius of
the narrowest opening (4 A˚) of hCtr1 [45]. Moreover, we
previously demonstrated that cisplatin, like copper, can
induce conformational stabilization of trimeric hCtr1 [13].
The dynamic nature of the interactions between cisplatin
and its transporter has to be taken into consideration when
modeling the molecular basis of hCtr1-mediated transport.
Extracellular copper exists in an oxidized form (Cu2?) but
is reduced to Cu? by the membrane-bound cupric reduc-
tases [46] before transport. Thus, the activated cisplatin
intermediate also shares a similar charge content as in Cu?.
It has been proposed that the activated cisplatin may use
methionine-based intermolecular sulfur–sulfur exchange
along the axis of trimeric hCtr1 to facilitate its transport
[44], much like the mechanism underlying Cu(I) or
Ag(I) transport by the CusA efflux pump in bacteria [47].
This mechanism is consistent with the recently proposed
model describing how Cu(I) ions pass through the trans-
porter [7, 48]. Given that hCtr1-mediated cisplatin trans-
port shares many similarities with transport of copper,
including most of the proposed binding sites [13], it is
likely that the proposed model could be shared by cisplatin
transport.
Upregulated hCtr1 and accumulation of cellular cis-
platin were seen in cisplatin-treated cells (see Fig. 4a, left).
However, it is difficult to assign the extent by which
upregulated hCtr1 contributed to the overall cellular plat-
inum accumulation, because the level of cisplatin (which is
a substrate) was also increased in the system. Induction of
J Biol Inorg Chem (2014) 19:17–27 25
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hCtr1 expression by a copper-lowering agent takes several
hours to reach a plateau, but requires 72–96 h to return to
its basal level after the agent is removed [14]. We also
showed that treating cells with CuSO4 resulted in accu-
mulation of cellular copper content (see Fig. 4a, right),
whereas expression of hCtr1 was downregulated in cells
treated with copper [18, 49]. A plausible explanation to
account for these results is increased hCtr1 transport
activity, because expression of copper efflux transporters
(ATP7A and ATP7B) is not regulated by acute environ-
mental copper changes [6, 14]. These results demonstrated
that the capacities of cellular copper or cisplatin accumu-
lations cannot be simply related to the abundance of hCtr1
when cells are exposed to its substrates; rather, they are
controlled by the overall copper homeostasis system, which
involves interregulatory components consisting of copper,
hCtr1, and Sp1 [6]. Consistent with this model, we showed
that although cisplatin treatment induced hCtr1 expression,
cellular copper levels were reduced (Fig. 4b), suggesting
that cisplatin is a competitor for hCtr1-mediated copper
transport.
This argument may explain why addition of copper
suppressed cisplatin-induced hCtr1 expression yet no
reduction in overall cytotoxicity was found. Furthermore,
both cisplatin and copper are potent pro-oxidants with
many cellular lethality targets. The complexity of the
cytotoxic mechanisms of cisplatin and copper, especially
when in combination, cannot be explained by the expres-
sion of hCtr1 alone.
We found that Ag(I) and Zn(II) can also induce Sp1/
hCtr1 expression, which can be explained by the same
mechanism in that these metals may compete against
hCtr1-mediated copper transport, resulting in reduced cel-
lular copper levels and thereby upregulated Sp1/hCtr1.
Because the major influx transporter for Zn(II) is the
SLC39 family [50], the physiological implication of hCtr1
upregulation by Zn(II) remains to be evaluated. However,
it has been reported that zinc supplement can enhance the
treatment efficacy of platinum-based chemotherapy in
nasopharyngeal carcinoma [51]. Likewise, several organs
in silver-fed mice exhibited rates of cisplatin uptake dif-
ferent from those in normal-diet-fed mice [52], suggesting
that Ag(I) may affect the pharmacodynamics of platinum
drugs in cancer chemotherapy. In contrast, we found that
Cd(II) suppresses Sp1 expression (and therefore hCtr1
expression), most likely owing to Cd(II)-induced damage
to the DNA-binding zinc finger motifs of Sp1 [34]. Cd(II)
is a potent environmental poison, as are Ag(I) and Zn(II) to
lesser extents. The current study provides important
insights into how these heavy metals may affect copper
metabolism through interventions in copper homeostasis
regulation.
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